AMRX at a glance
Amneal Pharmaceuticals, Inc. (AMRX, SEC CIK 1723128) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 10, 2026 and Form 4 insider filings as recently as September 21, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Amneal Pharmaceuticals, Inc. (AMRX) reported revenue of $3.0 billion (up 8.0% from FY2024) and net income of $72.1 million. Diluted EPS was $0.22.
- As of June 30, 2026, 34 institutional investment managers tracked by SignalX reported holding Amneal Pharmaceuticals, Inc. (AMRX) shares worth $1.4 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Kiely John on August 13, 2026 of 50,000 shares at $17.64 per share.
- In the last 90 days, AMRX insiders reported 0 open-market purchases ($0) and 4 open-market sales ($7.2M) on Form 4, a net sale of $7.2M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $3.0B
- +8.0% vs prior year
- Insiders · 90 days
- 0 buys · 4 sells
- Net −$7.2M
- 13F holders
- 34 funds
- $1.4B · +0 vs prior quarter
- Latest 8-K
- Aug 10, 2026
- Item 1.01 · Item 3.02 · Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Development and commercialization of complex generic and branded pharmaceutical products focusing on high-barrier, high-value formulations
- New product emphasis: Launch of five oncology biosimilars including Boncresa™ and Oziltus™ FDA-approved in Dec 2025, plus first complex inhalation aerosol generics from Ireland facility
- Strategic shift: Expanded respiratory platform with injectable drug/device combos and long-acting injectables targeting hospital sector growth
- Quantitative highlight: Pipeline includes 61 pending ANDAs, 43 in development with 95% non-oral solids, FDA approval of multiple key respiratory and biosimilar products in 2025
- Noteworthy fact: First commercial approvals for products produced at new Ireland manufacturing facility in 2025, signifying geographic and complexity expansion
Risk Factors
- Tax Receivable Agreement (TRA) liability contingent $129.1M as of Dec 31, 2025 from basis adjustments under IRC Section 754
- Geopolitical exposure not specified; no direct mention of macroeconomic or international risk in text
- Litigation and government investigations with uncertain outcomes; accruals based on low end of probable loss range
- Potential volatility in tax valuation allowance reversals impacting contingent TRA liabilities and related income statement charges
Management Discussion & Analysis
- Net cash from operating activities $340.0M in 2025 vs $295.1M in 2024; 15.2% increase but lower YoY excluding $52.4M prior litigation settlement
- Net cash used in investing activities $112.3M in 2025 vs $63.0M in 2024; 78.2% increase due to higher capex and property deposits
- Net cash used in financing activities $31.5M in 2025 vs $211.8M in 2024; 85.1% decrease due to debt refinancing and related party note repayment
- Goodwill allocated: Specialty $366.3M, Affordable Medicines $159.7M, AvKARE $69.5M; no goodwill impairment in 2025
- Management identified critical accounting estimates in sales deductions, business combinations, goodwill impairment, income taxes, and contingencies
AI summary of the AMRX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Operating cash flow $48.0M used vs $91.2M provided YoY for six months ended June 30, 2026
- Cash used in investing $144.5M vs $44.3M YoY, including $75.0M product-rights payment
- Cash provided by financing $20.3M vs $80.9M used YoY, driven by $120.5M higher debt-financing inflows
- Kashiv acquisition cash consideration $375M, expected third-quarter 2026 closing, funded through cash and borrowings
- Future opioid-settlement payments $97.6M through March 2034, including $12.7M due March 1, 2027
Risk Factors
- Risk factors not provided; excerpt begins with supplemental disclosure reference
- Kashiv Biosciences acquisition agreement dated April 21, 2026, introducing transaction-integration exposure
- Restrictive covenant agreements with Chirag and Chintu Patel dated April 21, 2026, indicating management-continuity considerations
AI summary of the AMRX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.01: Entry into a Material Definitive Agreement
- $350 million incremental term loan from Bank of America funded acquisition consideration
- Debt increased through Amendment No. 3 Term Loan expansion under Amneal’s existing credit agreement
Item 3.02: Unregistered Sales of Equity Securities
- Amneal issued 28,942,098 Class A shares to acquisition sellers as stock consideration
- Transaction used Section 4(a)(2) private-placement exemption, avoiding immediate Securities Act registration
Item 7.01: Regulation FD Disclosure
- Amneal completed the Acquisition, marking a transition from announced transaction to closed deal
- Exhibit 99.1 press release contains transaction details and expected strategic implications
Item EX-99.1: Item EX-99.1
- Completed Kashiv acquisition, creating an integrated biosimilars platform spanning R&D, manufacturing, and commercialization
- Biosimilars become a major long-term growth pillar, extending Amneal’s growth profile into the 2030s
Item 1.01: Entry into a Material Definitive Agreement
- Amendment No. 3 modifies Amneal Pharmaceuticals LLC’s term-loan credit agreement with JPMorgan Chase Bank as administrative agent
- Repricing amendment targets borrowing-cost savings, potentially improving cash flow and debt-service capacity
Item 5.07: Submission of Matters to a Vote of Security Holders
- Stockholders approved Kashiv acquisition, clearing a key closing condition under the Purchase Agreement
- Stock issuance approved for 28,942,108 shares to Kashiv sellers, creating meaningful dilution for existing holders
AI summaries of AMRX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for AMRX
Don't miss the next AMRX filing
- Alerts as it files. A push when AMRX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut AMRX, by share count.
- Ask anything. An AI agent that reads every AMRX filing and answers with sources.
AMRX alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| BUCHI J KEVIN | G | Sep 17, 2026 | 20,445 | - |
| BUCHI J KEVIN | M | Sep 11, 2026 | 20,445 | - |
| BUCHI J KEVIN | M | Sep 11, 2026 | 20,445 | $14.45 |
| BOYER ANDREW S | G | Sep 1, 2026 | 80,000 | - |
| BOYER ANDREW S | G | Aug 21, 2026 | 152,426 | - |
| Kiely John | G | Aug 13, 2026 | 10,000 | - |
| Kiely John | Sell | Aug 13, 2026 | 50,000 | $17.64 |
| Daly Jason B. | Sell | Aug 12, 2026 | 210,000 | $17.40 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $2.4B | $2.8B | $3.0B |
| Gross Profit | - | $1.0B | $1.1B |
| Operating Income | - | $249.3M | $394.1M |
| Net Income | - | -$116.9M | $72.1M |
| Gross Margin | - | 36.5% | 36.9% |
| Op. Margin | - | 8.9% | 13.1% |
| Net Margin | - | -4.2% | 2.4% |
| Balance Sheet | |||
| Total Assets | - | $3.5B | $3.7B |
| Equity | $19.8M | -$109.3M | -$70.8M |
| ROE | - | 107.0% | -101.8% |
| Per Share | |||
| EPS | - | $-0.38 | $0.22 |
| Cash Flow | |||
| Operating CF | - | $295.1M | $340.0M |
| CapEx | - | $51.9M | $70.1M |
Source: XBRL data in Amneal Pharmaceuticals, Inc. (AMRX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate AMRX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 34 | $1.45B |
| Q1 2026 | 34 | $1.00B |
| Q4 2025 | 30 | $899.3M |
| Q3 2025 | 30 | $698.1M |
| Q2 2025 | 29 | $539.3M |
| Q1 2025 | 26 | $408.9M |
| Q4 2024 | 20 | $341.6M |
| Q3 2024 | 18 | $220.2M |
- BlackRock+2.04M (+8%)
- Vanguard Portfolio Management LLC+812.8K (+7%)
- State Street Corp+562.3K (+8%)
- Citadel Advisors LLC+541.3K (+94%)
- Wells Fargo & Co+317.3K (+302%)
- D.E. Shaw & Co−945.9K (-55%)
- Morgan Stanley−527.2K (-11%)
- Millennium Management−355.0K (-96%)
- Ameriprise Financial−283.3K (-15%)
- Renaissance Technologies LLC−189.2K (-68%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 221 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
AMRX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 21, 2026 | - | - | - |
| 4 | Sep 14, 2026 | - | - | - |
| 4 | Sep 2, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 8-K | Jul 31, 2026 | - | Analysis | - |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 4 | May 12, 2026 | - | - | |
| 4 | May 8, 2026 | - | - | |
| 4 | May 8, 2026 | - | - | |
| 4 | May 8, 2026 | - | - | |
| 4 | May 8, 2026 | - | - | |
| 4 | May 8, 2026 | - | - | |
| 4 | May 8, 2026 | - | - | |
| 4 | May 8, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
AMRX SEC filings: frequently asked questions
Are AMRX insiders buying or selling?
In the last 90 days, Amneal Pharmaceuticals, Inc. (AMRX) officers, directors and 10% owners reported no open-market purchases and 4 open-market sales worth $7.2 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold AMRX stock?
As of June 30, 2026, the largest Amneal Pharmaceuticals, Inc. (AMRX) holders among the 13F filers tracked by SignalX were BlackRock ($459.8 million), Vanguard Portfolio Management LLC ($210.1 million), Vanguard Capital Management LLC ($133.5 million), State Street Corp ($127.3 million), Dimensional Fund Advisors ($100.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was AMRX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Amneal Pharmaceuticals, Inc. (AMRX) reported revenue of $3.0 billion (up 8.0% from FY2024) and net income of $72.1 million. Diluted EPS was $0.22. The figures come from the XBRL data in the 10-K.
What are the main risks in AMRX's latest 10-K?
In the 10-K filed February 27, 2026, Amneal Pharmaceuticals, Inc. (AMRX) flagged: Tax Receivable Agreement (TRA) liability contingent $129.1M as of Dec 31, 2025 from basis adjustments under IRC Section 754. Geopolitical exposure not specified; no direct mention of macroeconomic or international risk in text. (AI summary of the Risk Factors section.)
What did AMRX report in its latest 8-K?
Amneal Pharmaceuticals, Inc. (AMRX) filed an 8-K on August 10, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 3.02 (Unregistered Sales of Equity Securities) and Item 7.01 (Regulation FD Disclosure). $350 million incremental term loan from Bank of America funded acquisition consideration.
What are the latest AMRX SEC filings?
Amneal Pharmaceuticals, Inc. (AMRX) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 10, 2026 and a Form 4 insider filing on September 21, 2026.
What is AMRX's SEC CIK number?
Amneal Pharmaceuticals, Inc. (AMRX)'s SEC Central Index Key (CIK) is 1723128. EDGAR lists every AMRX filing under that number.
Ask anything about AMRX
The research agent reads AMRX's filings, financials, insider trades and 13F holders, then answers with sources.